skin and soft tissue infections (S. aureus)(Preclinical)
Status note Preclinical; potential prophylactic and therapeutic use.
EVX-B2
Preclinical · ActiveModality: vaccine
Target N. gonorrhoeae antigens
Partnerships Afrigen (collaboration)
Indications
gonorrhea(Preclinical)
Status note Preclinical proof of concept.
EVX-B3
Stage not disclosed · ActiveModality: vaccine
Partnerships MSD (Merck & Co., Rahway, NJ; licensed 2025 for $7.5M; Evaxion eligible for development, regulatory and sales milestones and royalties on net sales)
Indications
undisclosed bacterial pathogen(Stage not disclosed)
Status note Licensed to MSD for $7.5M upfront in 2025; Evaxion eligible for future development, regulatory and sales milestones and royalties.
EVX-B4
Preclinical · ActiveModality: vaccine
Target Group A Streptococcus antigens
Indications
Group A Streptococcus infection(Preclinical)
Catalysts
— H2 2026
Status note Preclinical.
EVX-V1
Stage not disclosed · ActiveModality: multi-component prophylactic vaccine
Target CMV antigens
Indications
cytomegalovirus (CMV) infection (e.g., solid organ transplant)(Stage not disclosed)
Status note Stage not stated in filing.
Per-asset detail extracted from the 20-F filed 2026-03-05. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
No specialist-fund holders in 13F data for this company.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 714 stocks.